Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
data privacy protection Impressum
Home
Research
Research Topics
Cancer Risk Factors and Prevention
Health Economics

Research

Karla Hernández-Villafuerte, PhD

Karla Hernández-Villafuerte, PhD

Karla Hernández-Villafuerte, PhD

Position:

External Collaborator

E-mail:

k.hernandezvillafuerte@dkfz.de

Formally the senior researcher of our Division (August 2017-June 2022), Dr. Karla Hernandez-Villafuerte currently serves as a senior economist at the WifOR Institute in Darmstadt. She has vast experience in examining factors that influence the decision making process for the reimbursement of new medicines. Currently, she is developing a holistic micro- and macro-economic impact evaluation tool for assessing the overall economic impact of new health technologies.

At the Division of Health Economics at the DKFZ, she was a primary investigator in evaluating the efficacy of multi-attribute utility instruments that reflect quality of life of cancer patients, and she had a lead role in creating a framework for assessing the research and development costs of a new medicine. In addition, she has been instrumental in projects examining the socioeconomic impact of cancer on patients and their families/caregivers.

Prior to working the DKFZ, Karla was part of the Office of Health Economics (OHE) in London. Her work at the OHE included a variety of research projects. These included the evaluation of statistical and health economic issues in cancer survival and analysis of the evolution of HTA in developing countries within the International Decision Support Initiative (iDSI). She has a PhD in economics from the University of Göttingen in Germany and a master's degree in economics from the University of Costa Rica.

 

Selected Publications

K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Estimating health system opportunity costs: the role of non-linearities and inefficiency.
Cost Effectiveness and Resource Allocation, 2022: 20(1), 56.
DOI: 10.1186/s12962-022-00391-y.

M. Schlander, K. Hernandez-Villafuerte, C. -Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:
How much does it cost to research and develop a new drug? A systematic review and assessment.
Pharmacoeconomics, (2021) 39(11) 1243-1269.
DOI: 10.1007/s40273-021-01065-y.

K. Hernandez-Villafuerte, A. Fischer, N. R. Latimer:
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology.
International Journal of Technology Assessment in Health Care, (2018) 34(3) 300-316.
DOI: 10.1017/S0266462318000338.

to top
powered by webEdition CMS